SPRIM’s Quarterly Ventures Day Meeting in New York

SPRIM Ventures in partnership with Tikehau Capital is hosting a Ventures Day event in New York on April 24. … Read More 

Fibronostics Corporate Update

Fibronostics presented its corporate strategy at the second annual TKS 1 Investor Day in Singapore. The event was attended by current and potential investors in the TKS 1 fund, including venture capitalists, strategic investors, family offices and leaders from the healthcare industry. … Read More 

Evid Science: AI Can Read & Share the Latest Medical Research with Doctors

Evid Science’s founder and CEO, Matt Michelson, spoke to Thrive Global about the future of healthcare and how AI is transforming the industry. Evid Science is helping to “free” all of the scientific data locked away in publications and journals.   … Read More 

Objective GI Funding Announcement

Objective GI, a gastrointestinal-focused clinical research company, announces a key investment by TKS 1, a joint venture between SPRIM and Tikehau Capital, enabling the company to grow its network of GI-specialty clinical research sites in the United States. … Read More 

TKS 1 Investor Day 2019 in Singapore: Post Event Highlights

Going strong in its second time, together with Tikehau Capital, SPRIM held TKS 1 Investor Day on Friday, January 25, 2019, at the Four Seasons Hotel in Singapore. We invited all teams, shareholders, and partners of the ventures for this event … … Read More 

RegAsk, a Healthcare RegTech Startup, Secures Venture Capital Funding in a Seed Round to Pursue Growth

RegAsk uses artificial intelligence to answer regulatory questions, including inquiries about path-to-market, path-to-claim, product registration and regulatory strategy. … Read More 

Startups Aim to Fix ‘Broken’ Clinical Trials System

ObvioHealth, meanwhile, has developed an app that enables studies to be run using mobile devices. Data from smart devices such as a Bluetooth blood pressure monitor can integrate with the app, according to the company, which earlier this year raised … Read More 

ObvioHealth’s Milo Demonstrates How Digital Technology Improves Patient Experience, Compliance and Data Capture Using ClaimIt.

MILO & CLAIMIT View a short, imagined study where ObvioHealth’s Milo demonstrates how digital technology improves patient experience, compliance and data capture using ClaimIt. Follow our fictional subject, Milo, as he uses his mobile phone to participate in a clinical … Read More 

Solving the Blood‑Brain Barrier Challenge

The blood brain barrier (BBB) is a system of blood vessels that protects the brain from toxins and chemical fluctuations. While it is necessary to help keep the brain healthy, it also poses a problem in delivering medications that could … Read More 

3 Ways Mobile Clinical Trials Help Clinical Researchers Improve Diversity

Lack of diversity within the clinical trial industry poses a grave problem. We cannot assume medicines work similarly across ethnicities. While attracting and retaining minority groups to participate in clinical trials has become a primary focus in the industry, many … Read More 

Evid Science Receives Seed Capital to Advance Clinical AI Platform

LOS ANGELES, CA (February 15, 2018) – Evid Science, an artificial intelligence (AI) company for the pharmaceutical industry, has successfully secured seed funding from TKS I, a new private equity fund dedicated to early-stage life science companies. “Our technology is … Read More 

Duke-NUS Commercializes Discovery to Deliver Therapeutics Across Blood Brain Barrier

Intellectual property (IP) derived from discoveries made at Duke-NUS Medical School (Duke-NUS) have been licensed to a newly formed biotech start-up, Travecta Therapeutics Pte Ltd, a Singapore-based drug discovery company. Travecta plans to use the Duke-NUS technology to develop new … Read More 

Tackling the blood-brain barrier: Duke-NUS discovery leads to startup Travecta

HONG KONG – Travecta Therapeutics Pte Ltd. is the latest startup to join Singapore’s biotech block. The newly formed drug discovery company is based on intellectual property derived from discoveries made at Duke-NUS Medical School (Duke-NUS). Travecta is based on … Read More 

SPRIM and Tikehau Capital Join Forces with New Singapore-based Life Sciences VC Fund

LIFE science startups hoping for a big break can now look to a new Singapore-based cash cow for funding.European asset manager Tikehau Capital and Sprim Ventures, the venture arm of global healthcare consultancy Sprim, have teamed up to launch a … Read More 

Travecta Therapeutics Appoints Douglas C. Hicks as Chief Business Officer

PHILADELPHIA — Sept. 13 2018 – Travecta Therapeutics, an emerging biotech company developing a platform that leverages its proprietary knowledge of the MFSD2a Transport for the targeted delivery of therapeutic agents across the blood-brain barrier, announces it has appointed Douglas … Read More 

ObvioHealth Announces Mobile Application

ORLANDO, Fla.–(BUSINESS WIRE)–ObvioHealth, a global medical technology company, announces the launch of its mobile application for site-less clinical studies—ClaimIt. ClaimIt removes barriers currently troubling the clinical research industry by improving convenience for study subjects, enhancing compliance, lowering drop-out rates and … Read More 

ObvioHealth Raises $3 Million in Series A Funding

ObvioHealth, a Singapore and Orlando-based company offering mobile and “site-less” clinical trials, said on Friday it has raised US$3 million in Series A funding. The company is focused on making clinical trials faster and more cost-effective by digitizing the entire process … Read More